Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York State

Erica Lasek-Nesselquist, Pascal Lapierre, Erasmus Schneider, Kirsten St. George, View ORCID ProfileJanice Pata
doi: https://doi.org/10.1101/2021.02.26.21251868
Erica Lasek-Nesselquist
1Wadsworth Center, New York State Department of Health, 120 New Scotland Avenue, Albany, NY 12208, USA
2Department of Biomedical Sciences, School of Public Health, University at Albany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: erica.lasek-nesselquist@health.ny.gov
Pascal Lapierre
1Wadsworth Center, New York State Department of Health, 120 New Scotland Avenue, Albany, NY 12208, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erasmus Schneider
1Wadsworth Center, New York State Department of Health, 120 New Scotland Avenue, Albany, NY 12208, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kirsten St. George
1Wadsworth Center, New York State Department of Health, 120 New Scotland Avenue, Albany, NY 12208, USA
2Department of Biomedical Sciences, School of Public Health, University at Albany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janice Pata
1Wadsworth Center, New York State Department of Health, 120 New Scotland Avenue, Albany, NY 12208, USA
2Department of Biomedical Sciences, School of Public Health, University at Albany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Janice Pata
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The E484K mutation in the spike protein of SARS CoV-2 contributes to immune escape from monoclonal antibodies as well as neutralizing antibodies in COVID-19 convalescent plasma. It appears in two variants of concern – B.1.351 and P.1 - but has evolved multiple times in different SARS-CoV-2 lineages, suggesting an adaptive advantage. Here we report on the emergence of a 484K variant in the B.1.526 lineage that has recently become prevalent in New York State, particularly in the New York City metropolitan area. In addition to the E484K mutation, these variants also harbor a D235G substitution in spike that might help to reduce the efficacy of neutralizing antibodies.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Initial funding for sequencing was generously provided by the New York Community Trust. This publication was also supported by Cooperative Agreement number NU50CK000516, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This work was approved by the New York State Department of Health Institutional Review Board, under study numbers 02-054 and 07-022.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Genome sequences and metadata are available at GISAID.org

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 01, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York State
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York State
Erica Lasek-Nesselquist, Pascal Lapierre, Erasmus Schneider, Kirsten St. George, Janice Pata
medRxiv 2021.02.26.21251868; doi: https://doi.org/10.1101/2021.02.26.21251868
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York State
Erica Lasek-Nesselquist, Pascal Lapierre, Erasmus Schneider, Kirsten St. George, Janice Pata
medRxiv 2021.02.26.21251868; doi: https://doi.org/10.1101/2021.02.26.21251868

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1095)
  • Dentistry and Oral Medicine (195)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9764)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2304)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1555)
  • Health Policy (734)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11637)
  • Intensive Care and Critical Care Medicine (616)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2140)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1174)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (310)
  • Pediatrics (694)
  • Pharmacology and Therapeutics (299)
  • Primary Care Research (266)
  • Psychiatry and Clinical Psychology (2179)
  • Public and Global Health (4653)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (250)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)